NAT GENET:甲基化单倍型区域的鉴定有助于鉴定异质性组织样品的反褶积和对来自血浆DNA的肿瘤组织来源定位作图

2017-03-18 MedSci MedSci原创

哺乳动物基因组中的相邻CpG位点可由甲基转移酶或脱甲基酶的持续合成能力而产生共甲基化,但也会观察到不一致的甲基化模式,这与随机或不协调的分子进程相关。研究发现甲基化单倍型区域的鉴定有助于鉴定异质性组织样品的反褶积和对来自血浆DNA的肿瘤组织来源定位作图。

哺乳动物基因组中的相邻CpG位点可由甲基转移酶或脱甲基酶的持续合成能力而产生共甲基化,但也会观察到不一致的甲基化模式,这与随机或不协调的分子进程相关。来自加州大学圣地亚哥分校(UCSD)的生物工程师根据这些特征开发了一种检测癌症的新方法。相关研究成果于近日发表在NatureGenetics上。

研究人员通过系统搜索和调查全人类基因组中显示高度协调的甲基化区域。在对61个全基因组亚硫酸氢盐测序数据集的分析和101个简化亚硫酸氢盐测序数据集和637个甲基化阵列数据集的验证后,定义了具有紧密耦合的CpG位点的147,888各区域,称为甲基化单倍型区域。使用甲基化单倍型负载的度量,在区域水平执行组织特异性甲基化分析。对信息区域的子集进一步用于鉴定异质性样品的反褶积。

最后,通过使用甲基化单倍型技术,研究人员能够对59例肺癌或结肠直肠癌患者的循环DNA进行定量评估肿瘤负荷并对组织来源定位作图。

原始出处:
Shicheng Guo, Dinh Diep, Kun Zhang,et al.Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA.  Nature Genetics (2017) doi:10.1038/ng.3805

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881759, encodeId=87701881e59df, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 08 03:00:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733828, encodeId=2e651e338289a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Feb 02 21:00:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048787, encodeId=d4272048e8718, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Nov 12 14:00:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686062, encodeId=a59316860622b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Dec 08 18:00:00 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2017-08-08 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881759, encodeId=87701881e59df, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 08 03:00:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733828, encodeId=2e651e338289a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Feb 02 21:00:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048787, encodeId=d4272048e8718, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Nov 12 14:00:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686062, encodeId=a59316860622b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Dec 08 18:00:00 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2018-02-02 canlab
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881759, encodeId=87701881e59df, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 08 03:00:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733828, encodeId=2e651e338289a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Feb 02 21:00:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048787, encodeId=d4272048e8718, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Nov 12 14:00:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686062, encodeId=a59316860622b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Dec 08 18:00:00 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2017-11-12 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=1881759, encodeId=87701881e59df, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 08 03:00:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733828, encodeId=2e651e338289a, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Feb 02 21:00:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048787, encodeId=d4272048e8718, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Nov 12 14:00:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686062, encodeId=a59316860622b, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Fri Dec 08 18:00:00 CST 2017, time=2017-12-08, status=1, ipAttribution=)]

相关资讯

免疫检查点抑制剂的“心理阴影面积”

全球 1000 多个以 PD-1,PD-L1 等生物标志物为靶标的临床试验正在进行当中,横扫多个血液肿瘤及实体瘤适应症。FDA 也趁势为这些创新产品授予了 13 个突破性疗法认定。国内研发免疫检查点抑制剂的热情也是一哄而上,仿佛看到了一座座闪光的金矿。

2017肿瘤研究的十大方向是什么?

一、肿瘤的遗传学基础肿瘤的遗传学基础是现代肿瘤研究的基石。早在20世纪初,科学家就发现,细胞的异常有丝分裂和恶性肿瘤有关。20实际中叶,DNA双螺旋结构的发现,明确了遗传物质的遗传机理,科学家进一步发现,在癌症细胞中,染色体不稳定可以促使染色体异常和突变积累。 随着研究的深入,有一个假设被越来越多的研究人员所接受:染色体异常和基因组不稳定是癌症发生的始动因素。二、肿瘤免疫肿瘤的免疫

CLIN CHEM:基于纸基的血浆和循环肿瘤细胞微小RNA表达谱

常规分离的循环肿瘤细胞受白细胞和红细胞污染使得循环肿瘤细胞特异性分子特征的鉴定极为困难。一种纸基的提取方法可以从有限的生物样品中最大限度地回收miRNA并进行下游分子分析。

PNAS:杀癌的CD8+T细胞与失活的CD8+T细胞在基因组和表达上的区别

杀癌的CD8+T细胞与失活的CD8+T细胞在基因组和表达上的区别

盘点:肿瘤治疗领域近期进展汇总

武田风投资本 Takeda Ventures 近期与 Arix Bioscience 达成一项战略性合作。这项合作意味着 Takeda Ventures 携手 Arix,以投资 10-15 项早期生物技术项目。这项协议使得武田药品成为第二大同 Arix 合作的生物制药公司。此前,UCB 也已与其合作。

打破肿瘤生命封印的五种最佳治疗技术

肿瘤就像一把达摩克利斯之剑,时刻威胁着人类的生命安全,让人寝不能安。尽管肿瘤真面目在目前已经露出了冰山一角,但是针对肿瘤的治疗依然处于万里长征的第一步。而现阶段这五种尖端治疗手段无疑成为了发现肿瘤的“阿克琉斯之踵”的神兵利器,成为了打破肿瘤生命封印的重磅大锤!1、精准医学:解读基因的故事“精准医学”这个概念自奥巴马提出后,很快就风靡全球。但目前科研者们普遍认为,要真正实现抗肿瘤的精准医疗并非易